IaSON
Early Onset Immunotherapy by Intravenous Immunoglobulin in Well-characterized Onconeural-antibody-positive Paraneoplastic Neurological Syndromes
Sponsor study identifier
interventional
17
1 country
1
Study Start
November 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2016
Actual (reported)Study Completion
December 2016
Actual (reported)Paraneoplastic Neurological Syndromes (PNS) are rare remote effects of cancer, not directly attributed to mass lesions, metastases, infections, ischemia, coagulopathy, metabolic disruptions or tumour treatment. Currently, PNS treatment is mostly limited to tumour treatment. Because of an initial inflammatory stage early in the evolution of the PNS several immunotherapy modalities have been tried. Intravenous human immunoglobulins could be expected to provide a stabilization or even improvement of PNS, if administered early enough to prevent permanent neuronal damage.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2016
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2013
Date type not reportedThis date has not been verified as actual or estimated.
January 15, 2015
Actual (reported)January 21, 2015
Actual (reported)June 2016
Actual (reported)December 2016
Actual (reported)percentage of patients with neurological improvement after 3 months of immunotherapy with IVIg
"Success" is defined by ≥ 1 point lower score in the modified Rankin Scale (mRS) after treatment compared to baseline. "Failure" is defined by failure to meet the success definition.
3 months
percentage of patients with neurological improvement after 6 months of immunotherapy with IVIg
6 months
percentage of patients with improvement in Barthel Index (BI)
3 months
percentage of patients with improvement in Barthel Index (BI)
6 months
percentage of patients with improvement in International Cooperative Ataxia Rating Scale (ICARS),
3 months
percentage of patients with improvement in International Cooperative Ataxia Rating Scale (ICARS),
6 months
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Groupe Hospitalier Pitié Salpetrière
Paris, 75013, France
Berzero G, Karantoni E, Dehais C, Ducray F, Thomas L, Picard G, Rogemond V, Candelier G, Camdessanche JP, Antoine JC, De Seze J, Liou-Schischmanoff A, Honnorat J, Delattre JY, Psimaras D. Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies. J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):789-792. doi: 10.1136/jnnp-2017-316904. Epub 2017 Oct 30. No abstract available.
Dimitri Psimaras, MD
Assistance Publique - Hôpitaux de Paris
First Submitted
January 15, 2015
First Posted
January 21, 2015
Study Start
November 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2016
Actual (reported)Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)
Contact the study team to confirm eligibility.
Study Completion
December 2016
Actual (reported)Last Updated
November 6, 2017
Record last verified: 2017-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: